Investors who lost money with shares of Integer Holdings Corporation (NYSE: ITGR) should contact the Shareholders Foundation in connection with Lawsuit

An investor, who purchased shares of Integer Holdings Corporation (NYSE: ITGR), filed a lawsuit over alleged violations of Federal Securities Laws by Integer Holdings Corporation in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Integer Holdings Corporation (NYSE: ITGR) have certain options and for certain investors are short and strict deadlines running. Deadline: February 9, 2026. NYSE: ITGR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Plano, TX based Integer Holdings Corporation operates as a medical device contract development and manufacturing company in the United States, Puerto Rico, Costa Rica, and internationally.

The Company contracts with medical device companies to manufacture cardiac rhythm management and cardio and vascular ("C&V") medical devices. Integer's C&V product line generates approximately 60% of the Company's total revenue. As a part of the C&V product line, Integer manufactures electrophysiology ("EP") devices, which diagnose and map the heart's electrical activity to address problems such as irregular heartbeats (cardiac arrhythmias).
EP devices underwent a technological revolution as Integer customers began to develop devices for pulse field ablation ("PFA") procedures that use brief, high-energy electrical pulses to treat atrial fibrillation. In turn, the industry became increasingly focused on integrating EP devices and PFA platforms to effectuate a more seamless cardiac procedure. As a result, EP devices represented a significant growth driver for Integer's C&V segment.

Integer Holdings Corporation (NYSE: ITGR) reported that its annual Total Revenue rose from over $1.55 billion in 2023 to over $1.71 billion in 2024, and that its Net Income rose from $90.65 million in 2023 to $119.89 million in 2024.

Then on October 23, 2025, Integer Holdings Corporation disclosed that it had lowered its full-year 2025 sales guidance to a range between $1.840 billion and $1.854 billion, which fell short of analysts' estimates. Integer further disclosed that it expected net sales growth of -2% to 2% and organic sales growth of 0% and 4% for the full year of 2026. During the corresponding earnings call, COO Khales revealed that Integer "expect[s] sales of [three] new products to decline in 2026," with two of three being "electrophysiology [EP] products." COO Khales further revealed that "the market adoption of these products has been slower than forecasted." During the same earnings call, CFO Smith informed investors that, for the fourth quarter of 2025, "we expect C&V sales growth to decelerate from recent trends, reflecting a decline in the [two] new products in electrophysiology mentioned earlier. This is consistent with our prior outlook. However, we now expect this impact to continue into 2026, primarily the first half."

Shares of Integer Holdings Corporation (NYSE: ITGR) declined from $146.36 per share on January 30, 2025, to as low as $64.88 per share on October 31, 2025.

The plaintiff claims that between July 25, 2024 and October 22, 2025, the Defendants failed to disclose that Integer materially overstated its competitive position within the growing EP manufacturing market, that despite Integer's claims of strong visibility into customer demand, the Company was experiencing a sustained deterioration in sales relating to two of its EP devices, that in turn, Integer mischaracterized its EP devices as a long-term growth driver for the Company's C&V segment, that as a result of the above, Defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Those who purchased shares of Integer Holdings Corporation (NYSE: ITGR) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.